Nebulized Magnesium Sulfate in Children With Moderate to Severe Asthma Exacerbation

• Change in forced expiratory volume in one second (FEV1) [ Time Frame: Baseline and one hour after treatment ] [ Designated as safety issue: Yes ]
  Change in forced expiratory volume in one second (FEV1) as measured by bedside spirometry before and after study intervention.
  
  

• Change in Pediatric Asthma Severity Score (PASS) [ Time Frame: Baseline and one hour after treatment ] [ Designated as safety issue: Yes ]
  The change in Pediatric Asthma Severity Score (PASS) before and after administration of the study drug will be recorded
  
  
• Patients' Disposition [ Time Frame: 24 hours ] [ Designated as safety issue: Yes ]

  Patients' disposition will be monitored:

  • home
  • inpatient admission on intermittent albuterol
  • inpatient admission on continuous albuterol
  
  
• Length of Emergency Department (ED) stay [ Time Frame: 24 hours ] [ Designated as safety issue: Yes ]
  The length of stay in the Emergency Department (ED) will be monitored
  
  
• Return rates to the Emergency Department [ Time Frame: 72 hours ] [ Designated as safety issue: Yes ]
  Enrolled patients who return to the Emergency Department within 72 hours will be monitored and followed
  
  

Patients presenting to the Emergency Department for acute asthma exacerbation will receive standard care of up to three doses of albuterol and ipratropium bromide plus oral steroid medication. Those seven years of age and older who require further treatment will be screened for eligibility. Eligibility screening will comprise measurement of forced expiratory volume in one second (FEV1) with a bedside spirometer by a respiratory therapist. Children under the age of seven are generally unable to complete spirometry maneuvers and will thus be excluded. The Pediatric Asthma Severity Score (PASS) will also be noted by a respiratory therapist. Patients able to complete spirometry testing and with an FEV1 less than 70% of predicted (the definition of moderate asthma exacerbation) will be enrolled. Enrolled patients will be randomized to receive either Children's Medical Center standard care of 15 mg albuterol diluted in 22 ml of normal saline or the study intervention of 15 mg of albuterol diluted in 22 ml of magnesium sulfate solution. This solution will be prepared at the time of use by a pharmacist in the Emergency Department and will consist of 22 ml of a commercially available 40 mg/ml magnesium sulfate solution (880 mg). The nebulizer treatment will be given over approximately one hour via a large volume nebulizer at 25 ml/hr. Physicians, nurses, and respiratory therapists will be blinded to the diluent used. Vital signs will be noted at baseline. Heart rate, heart rhythm, respiratory rate, and pulse oximetry will be monitored continuously while blood pressure will be measured at baseline and every 15 minutes during study medication administration. The study physician, treating physician, and/or bedside nurse will monitor these values for any clinically significant changes. At the end of the 15 mg albuterol treatment FEV1 and PASS will again be noted. Any further treatments needed, as determined by the treating physician, will be given following Children's Medical Center standard of care. At the discretion of the treating physician intravenous magnesium sulfate may be used post study intervention. The dose used for study participants will be the Children's Medical Center standard dose of 75 mg/kg (max 3 g) minus 880 mg to avoid the risk of magnesium sulfate overdose. Further treatments and patient disposition will be observed by study personnel and noted. Bounce-back rates will be collected by review of enrolled patients' medical record.